BIOSENIC S.A.

Organizations across the industry are leveraging real-world data to optimize strategies and drive growth. In this roundtable, hear from executives and scientists as they share best practices for using data to tackle business challenges. Read the roundtable here: https://lnkd.in/eHEZr5WR Our roundtable includes contributors from: Vectron Biosolutions AS, Alconox Inc., PPD part of Thermo Fisher Scientific, Dynamk Capital, Tanvex CDMO, Qualtrics, Astrea Bioseparations, epocrates, Triumvira Immunologics, Inc., eClinical Solutions, Rentschler Biopharma, MMIT (Managed Markets Insight & Technology), Catalent Pharma Solutions, LGM Pharma, LabVantage Solutions, Inc, TCG Digital, Rune Labs, Mission Bio, Vittoria Biotherapeutics, Inc., Alto Neuroscience, Elicio Therapeutics, Karius, OM1, Inc., Ori Biotech, Be The Match BioTherapies, ScaleReady, TrakCel, Terumo Blood and Cell Technologies, BioBridge Global, BIOSENIC S.A., and Lonza. #biotech #data #pharmaceuticalindustry #AI #Roundtable

In this roundtable from the close of 2023, we asked a panel of industry experts about the year's defining event in pharma/biopharma. Read the roundtable here: https://lnkd.in/da3fd6kj Our roundtable includes contributors from Be The Match BioTherapies, GBI Biomanufacturing, Lonza, Samsung Biologics, Tedor Pharma Services, Addimmune™, ADVI Health, Agilent Technologies, AnaptysBio, Astrea Bioseparations, Atomic AI, BioCina, BIOSENIC S.A., Bruker BioSpin, Cellares, CellProthera SAS, Click Therapeutics, Inc., CoRegen Inc., CRB, Cyclacel Pharmaceuticals, Inc., eClinical Solutions, Ellab - Validation & Monitoring Solutions, Elicio Therapeutics, Elixirgen Therapeutics, Inc., Enthought, Epocrates (use this one), Evonik, F2G, Faeth Therapeutics, HDT Bio, KBio, Likarda, LGM Pharma, Medicus Pharma Ltd., Mission Bio, MOBILion Systems, Inc., Newfront, Norstella, Nucleus RadioPharma, OM1, Inc., ... (cont.)

In case you missed it: in this Pharma's Almanac roundtable, a panel of industry experts weighs in on the most significant regulatory decision or guidance influencing biopharma in 2024 and beyond. Read the roundtable here: https://lnkd.in/g-yU58uV Our roundtable includes contributors from GBI Bio, Lonza, MilliporeSigma, PPD, Samsung Biologics, Tedor Pharma Services, ADVI Health, Agilent Technologies, Astrea Bioseparations, Atomic AI, BioBridge Global, BioIVT, BIOSENIC S.A., Bruker BioSpin, Cellares, Cyclacel Limited, eClinical Solutions, Ellab - Validation & Monitoring Solutions, Evonik, Faeth Therapeutics, HDT Bio, Likarda, LGM Pharma, Medicus Pharma Ltd., Mission Bio, MOBILion Systems, Inc., Newfront, Norstella, OM1, Inc., OrganaBio, Organon, Ori Biotech, OzUK, Pharmatech Associates, a USP company, PointClickCare, ScaleReady, SCIEX, SCTbio, Sernova, ...(cont) #Regulatory #Biopharma #Roundtable

📚 #ReadoftheWeek Carole Nicco, Chief Scientific Officer and Chief Operating Officer of BIOSENIC S.A., explains how the repurposing of legacy #smallmolecules drugs could be more advantageous than previously known, and suggests another chance for Arsenic. Read more here: https://bit.ly/45zYATf

Transforming Medicine with Arsenic Trioxide at #RedoxMedicine2024 by Carole Nicco, president of RMS. Dr. Nicco presented the journey of arsenic trioxide in modern healthcare at Redox Medicine 2024. ▪ Arsenic trioxide (ATO), historically used in medicine, is now a leading treatment for acute promyelocytic leukemia , achieving high cure rates. ▪ Biomarker-driven research has revealed ATO's mechanisms in autoimmune diseases like chronic graft-versus-host disease, guiding advanced phase 3 trials with companion diagnostics. Dr. Nicco highlighted ATO's roles in immune regulation, anti-fibrotic actions, and vascular remodeling, emphasizing its potential in personalized medicine. The #RMS thanks Dr. Nicco for sharing her experience and latest data in this insightful presentation. #RedoxMedicine2024 #ArsenicTrioxide #PersonalizedMedicine #ScientificLeadership #HealthcareInnovation

Just have a quick read to learn more! https://bit.ly/45zYATf Understanding and creating the opportunity for patients to have access to new and safe treatments is the goal of BIOSENIC S.A./MEDSENIC. Arsenic trioxide is an incredible #smallmolecules drug that could be more advantageous than previously known. #arsenic #arsenictrioxide #ATO #innovation

Want to know more about MEDSENIC / BIOSENIC S.A. Arsenic Trioxide? You can meet me in Paris during the Redox Medicine Society congress 2024. 🌐 More information about the conference agenda, speakers, attendees and registration : https://lnkd.in/dkNzFQZU. Among the speakers you will be able to meet : Bruce Freeman, Keynote Speaker, University of Pittsburgh, USA Miria Ricchetti, Keynote Speaker, Institut Pasteur, France Martin Bergo, Karolinska Institutet, Sweden Mario D. Cordero, Universidad Pablo de Olavide, de Sevilla, Spain Christel Marquette, CEA, France Zaher ElBeck, Karolinska Institutet and Uppsala University, Sweden Tamara Tomin, Technische Universität Wien, Austria Laurent Chatre, ISTCT CNRS-Université de Caen UMR 6030, France Rizzo Roberta, Università degli Studi di Ferrara, Italy Andrew Cumpstey, University of Southampton, United Kingdom Daniel Vaiman, INSERM, Institut Cochin, France Sayuri Miyamoto, USP - Universidade Cidade de São Paulo, Brazil Jumana Saleh, Sultan Qaboos University, Oman Radia Tamarat, INSTITUT DE RADIOPROTECTION ET DE SURETE NUCLEAIRE (IRSN), France Jeffrey A. Johnson, University of Wisconsin-Madison, USA George Spyrou, The Cyprus Institute of Neurology & Genetics, Cyprus Duncan Emerton, Vice-President of Citeline, United Kingdom Antonio Vila-Coro, IQVIA, Spain Stéphane Mouchabac, Greater Paris University Hospitals - AP-HP, France Maxime Barat, Université Paris Cité médecine and Hopital Cochin, France Thanks to our supporters: Citeline Clinical and Mitologics. #redox #medicine #innovation #biopharma

Would you like to meet our COO-CSO Dr. Carole Nicco to learn more about BioSenic future projects?  If you are attending Redox Medicine Society 2024, she will be happy to make an appointment with you at the RMS2024 in Paris, July 27-28. Please feel free to send her a personal message on LinkedIn with RMS2024 at the beginning of the text. #innovation #redox #medicine #biomarkers #arsenic #ATO

#OARSI 2024 is coming next week. A great opportunity for me and my collaborators to meet friends, and colleagues and to show our last achievement. I hope to meet you during the poster session. Poster 851 : A SINGLE INTRA-ARTICULAR INJECTION OF JTA-004 IS SAFE AND EFFICIENT FOR TREATING SYMPTOMS IN THE MOST SEVERELY AFFECTED KNEE OSTEOARTHRITIS PATIENTS – A MULTICENTER, RANDOMIZED, DOUBLE-BLING, PLACEBO AND ACTIVE TREATMENT CONTROLLED PHASE III CLINICAL TRIAL. Poster 852 : ORAL SYSTEMIC ENZYME COMBINATION REDUCES CARTILAGE DEGRADATION BIOMARKERS AND RELIEVES PAIN IN KNEE OSTEOARTHRITIS– A CROSS-OVER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY #osteoarthritis #biomarkers #inflammation #hyaluronic #rutoside #clinical #trial #placebo #patients #cartilage #joint Carole Nicco Melanie Uebelhoer Dr. Stefanie Rau Cécile Lambert Dubuc Jean-Emile BIOSENIC S.A. Nestlé Health Science Artialis OARSI - Osteoarthritis Research Society International

🔬 Dive into our successful preclinical data on ATO medication for controlling key symptoms of Systemic Sclerosis. 🎤 François Rieger, PhD, President of the Board and CEO of the BioSenic Group, said: “Our past data, including several animal models of autoimmune diseases and recent Phase 2 trials in systemic lupus erythematosus and chronic graft-versus-host-disease, have shown the remarkable therapeutic benefits of BioSenic’s liquid ATO solution for various autoimmune conditions with critical unmet medical needs. The more recent data for another serious autoimmune disease, systemic sclerosis, has given convincing preclinical evidence to support a Phase 2 trial for patients affected by this disease, which has no cure. The well-known safety of ATO’s pharmacologically active ingredient mean derived products, including an oral formulation (OATO), may follow FDA’s rapid 505(b)(2) regulatory path.” Read more : https://lnkd.in/dqaY2j_U 🔬 Plongez dans nos données précliniques concluantes sur le médicament ATO pour contrôler les principaux symptômes de la sclérose systémique. 🎤 François Rieger, PhD, président du conseil d'administration et Directeur Général de BioSenic a déclaré : "Nos données antérieures, y compris plusieurs modèles animaux de maladies auto-immunes et les récents essais de phase 2 sur le lupus érythémateux disséminé et la maladie chronique du greffon contre l'hôte, ont montré les avantages thérapeutiques remarquables de la solution liquide d'ATO de BioSenic pour diverses maladies auto-immunes dont les besoins médicaux critiques ne sont pas satisfaits. Les données plus récentes concernant une autre maladie auto-immune grave, la sclérose systémique, ont fourni des preuves précliniques convaincantes en faveur d'un essai de phase 2 pourles patients atteints de cette maladie incurable. La sécurité bien connue de la molécule pharmacologiquement active ATOsignifie que les produits dérivés, y compris une formulation orale (OATO), pourraient suivre la voie réglementaire rapide505(b)(2) de la FDA". En savoir plus : https://lnkd.in/dqaY2j_U #ATO #arsenic #SystemicSclerosis #biopharma #autoimmunediseases #biotech #preclinical Carole Nicco Francois Rieger véronique POMI Lieven Huysse Alexia Rieger Dominique Rongvaux - Gaïda, Yannick Allanore, Anne Cauvet